Engineered Liposomal Delivery of Human ACE2 Across the Blood–Brain Barrier Attenuated Neurogenic Hypertension
The blood-brain barrier (BBB) restricts the entry of therapeutic agents into the brain cardiovascular regulatory region, potentially contributing to drug-resistant hypertension. <b>Objective</b>: The objective of this study was to overcome this limitation by modifying PEGylated liposomes with transferrin (Tf) to facilitate Tf receptor binding at the BBB and penetratin (Pen), a cell-penetrating peptide, to enhance neuronal uptake. <b>Methods</b>: This study evaluated the efficacy of Tf-Pen-liposomes in delivering angiotensin-converting enzyme 2 (ACE2) or EGFP (control) genes across the BBB in rats. In addition, the therapeutic effect of intravenous administration of Tf-Pen-Lip carrying plasmid DNA encoding ACE2 (Tf-Pen-Lip-pACE2) was tested in a neurogenic hypertension model induced by intracerebroventricular (ICV) infusion of angiotensin II (Ang II) via osmotic pump implantation and brain cannulation. <b>Results</b>: Conjugation with Tf and Pen significantly enhanced liposome-mediated gene transfection in cultured cells and increased transport across an in vitro BBB model. In vivo, intravenous administration of Tf-Pen-Lip-pACE2 or Tf-Pen-Lip-pGFP successfully elevated ACE2 or EGFP expression, respectively, in the hypothalamic paraventricular nucleus (PVN). Chronic ICV infusion of Ang II produced a sustained increase in blood pressure and heart rate, accompanied by sympathetic overactivation and elevated arginine vasopressin (AVP) secretion, hallmarks of neurogenic hypertension. Notably, intravenous Tf-Pen-Lip-pACE2 treatment dramatically attenuated Ang II-induced neurogenic hypertension, whereas Tf-Pen-Lip-pGFP had no effect on pressor responses, sympathetic activity, or AVP secretion. <b>Conclusions</b>: This dual-functionalized liposomal delivery system effectively transported the ACE2 gene across the BBB into the brain, increased ACE2 expression, and markedly attenuated neurogenic hypertension following systemic administration.
Authors
- Chengwen Sun (ORCID: https://orcid.org/0000-0001-5889-8448)
- Richard Nii Lante Lamptey (ORCID: https://orcid.org/0000-0002-9659-9083)
- Bivek Chaulagain (ORCID: https://orcid.org/0000-0001-6782-2330)
- Jagdish Singh (ORCID: https://orcid.org/0000-0003-0253-2804)
- Yue Shen
- Gowthami Reddy Mareddy (ORCID: https://orcid.org/0000-0003-3183-3200)
Institutions
- North Dakota State University (US)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-10-14
- DOI
- https://doi.org/10.3390/pharmaceutics17101329
- Primary Topic
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00